I-MAB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.8 USD | -0.55% |
|
0.00% | -5.26% |
| 04-18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
| 04-15 | I-Mab Announces Chief Medical Officer Changes | CI |
Chart calendar I-Mab
af34c52.Bt8j1DwRXKojUTNjcC8UEc_Asf5Hs0D6nDV8_3k_Fc8.Z7JsoFl7OdNJNx4OAxdtR7awwKl3-AWy5EwsiAkHZJhAknqWZmJph20gVA~dd5f423bb72abd2bdf6ec7bb4455ea07
Upcoming events on I-Mab
Past events on I-Mab
| 11/04/2024 15:15 | Needham Healthcare Conference |
| 14/03/2024 21:00 | Q4 2023 Earnings Release |
| 30/11/2023 13:30 | Piper Sandler Healthcare Conference |
| 14/11/2023 10:30 | Jefferies London Healthcare Conference |
| 04/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Poster #: 792 |
| 03/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Abstract ID: 845 |
| 23/10/2023 11:00 | European Society for Medical Oncology Congress |
| 26/09/2023 19:10 | Cantor Global Healthcare Conference |
| 11/09/2023 16:30 | H.C. Wainwright Global Investment Conference |
| 17/08/2023 13:00 | Q2 2023 Earnings Call |
| 17/08/2023 11:00 | Q2 2023 Earnings Release |
| 03/06/2023 13:00 | American Society of Clinical Oncology Conference - Abstract No: 2570 |
| 31/03/2023 13:15 | Q4 2022 Earnings Call |
| 31/03/2023 11:30 | Q4 2022 Earnings Release |
| 12/12/2022 23:00 | American Society of Hematology Meeting - Abstract ID: 4462 |
| 12/12/2022 23:00 | American Society of Hematology Meeting - Abstract ID: 3974 |
| 10/11/2022 14:00 | Society for Immunotherapy of Cancer Meeting - Abstract ID : 859 |
| 10/11/2022 14:00 | Society for Immunotherapy of Cancer Meeting - Abstract ID: 1151 |
| 12/09/2022 | European Society for Medical Oncology Congress - Abstract #3823 |
| 12/09/2022 13:00 | European Society for Medical Oncology Congress |
Annual results
| Fiscal Period | December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 7,82 | 4,23 9,87 -57.18% | 236 185 27.81% | 13,8 84,4 -83.64% | -32,1 38,2 -183.99% | 3,89 2,72 43.36% |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -206 -171 -20.02% | 26,2 67,6 -61.22% | -311 -174 -78.68% | -268 -213 -26.01% | 0,00 0,00 - |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -206 -118 -74.27% | 23,8 34,5 -31.11% | -325 -179 -81.39% | -272 -232 -17.28% | -174 -168 -3.59% |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -205 -62,7 -226.47% | 73,9 37,2 98.35% | -366 -194 -88.63% | -350 -246 -41.96% | -206 -200 -3.02% |
|
Net income Million USD | Released Forecast Spread | 0,00 | -209 -62,7 -233.9% | 72,0 33,7 113.85% | -366 -195 -88.03% | -350 -246 -42% | -206 -200 -3.02% |
|
EPS USD | Released Forecast Spread | -8,97 | -65,4 -1,08 -5937.96% | 1,06 0,32 231.56% | -2,10 -1,83 -14.61% | -4,24 -2,08 -103.95% | -2,33 -1,77 -31.75% |
| Announcement Date | 29/07/19 | 31/03/20 | 29/03/21 | 29/03/22 | 31/03/23 | 14/03/24 |
Quarterly results
| Fiscal Period | December | 2020 S1 | 2020 Q4 | 2020 S2 | 2021 Q1 | 2021 Q2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 Q1 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 236 100 135.82% | 236 196 20.47% | 1,23 0,00 - | 1,23 0,00 - | 2,75 11,2 -75.42% | 4,87 0,00 - | 5,32 0,00 - | 11,0 73,0 -84.89% | 3,60 0,00 - | 3,60 0,00 - | 7,74 20,0 -61.29% | 0,00 | 0,00 | -39,9 25,0 -259.46% | 0,00 | 0,00 | 3,00 | 0,00 | 0,00 | 1,50 | 2,83 |
|
EBIT Million USD | Released Forecast Spread | -86,9 -64,3 -35.09% | 178 -59,6 398.52% | 118 112 5.15% | -66,4 -60,2 -10.25% | -66,4 -64,1 -3.52% | -159 -109 -45.31% | -67,6 -80,9 16.37% | -73,8 -87,3 15.48% | -164 -55,4 -196.14% | -56,9 -88,8 35.9% | -56,9 -90,3 36.98% | -122 -153 19.97% | -87,6 | -133 | -149 -88,8 -67.95% | -53,9 | -53,1 | -95,6 | -84,7 | -43,8 | -79,0 | -75,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -82,5 -63,5 -29.92% | 161 -59,6 370.07% | 163 102 59.13% | -74,9 -60,2 -24.39% | -74,9 -64,1 -16.81% | -167 -130 -28.68% | -87,1 -80,9 -7.65% | -95,0 -87,3 -8.8% | -197 -81,5 -141.56% | -72,6 -88,8 18.22% | -72,6 -90,3 19.58% | -156 -169 7.61% | -87,6 | -133 | -112 | -53,9 | -53,1 | -113 | -97,3 | -43,8 | -78,5 | -65,6 |
|
Net income Million USD | Released Forecast Spread | -82,5 -63,5 -29.92% | 159 -59,6 366.93% | 161 102 57.3% | -74,7 -60,2 -24.03% | -74,7 -64,1 -16.47% | -167 -130 -28.31% | -87,1 -80,9 -7.65% | -95,0 -87,3 -8.8% | -197 -81,5 -141.55% | -72,6 -88,8 18.22% | -72,6 -90,3 19.58% | -156 -169 7.61% | -87,6 | -133 | -112 | -53,9 | -53,1 | -113 | -97,3 | -43,8 | -78,5 | -65,6 |
|
EPS USD | Released Forecast Spread | -1,56 -1,10 -41.6% | 1,16 0,71 62.6% | 2,62 1,21 116.29% | -1,02 -0,36 -180.53% | -1,02 -0,38 -165.88% | -2,28 -1,25 -82.74% | -1,11 -0,48 -132.19% | -1,21 -0,51 -136.9% | -1,09 -1,28 14.54% | -0,88 -0,48 -83.73% | -0,88 -0,48 -82.59% | -1,90 -1,79 -5.99% | -0,47 | -0,70 | -2,34 -1,08 -116.67% | -0,28 | -0,27 | -1,31 | -0,85 | -0,22 | -0,55 | -0,48 |
| Announcement Date | 31/08/20 | 29/03/21 | 29/03/21 | 10/11/22 | 31/08/21 | 31/08/21 | 10/11/22 | 29/03/22 | 29/03/22 | 10/11/22 | 30/08/22 | 30/08/22 | - | - | 31/03/23 | - | - | - | - | - | - | - |
More events
Past sector events for I-Mab
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- IMAB Stock
- Calendar I-Mab
